Mirum Pharmaceuticals Inc (STU:08D)

€ 38.8 0.6 (1.57%) Market Cap: 1.92 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Q3 2024 Mirum Pharmaceuticals Inc Earnings Call Transcript
Nov 12, 2024

€40.2 (+3.08%)

Earnings
Q2 2024 Mirum Pharmaceuticals Inc Earnings Call Transcript
Aug 07, 2024

€35.4 (-1.67%)

Earnings
Q1 2024 Mirum Pharmaceuticals Inc Earnings Call Transcript
May 08, 2024

€23 (-4.96%)

Earnings
Q4 2023 Mirum Pharmaceuticals Inc Earnings Call Transcript
Feb 28, 2024

€27 (+2.27%)

Earnings
Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Mirum Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Nov 08, 2023
Q3 2023 Mirum Pharmaceuticals Inc Earnings Call Transcript
Nov 02, 2023

€26.6 (+3.91%)

Earnings
Mirum Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 28, 2023
Mirum Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 Mirum Pharmaceuticals Inc Earnings Call Transcript
Aug 03, 2023

€22.6

Earnings
Mirum Pharmaceuticals Inc To Acquire Travere Therapeutics Inc Call Transcript
Jul 17, 2023
Q1 2023 Mirum Pharmaceuticals Inc Earnings Call Transcript
May 04, 2023

€25.2 (+3.28%)

Earnings
Q4 2022 Mirum Pharmaceuticals Inc Earnings Call Transcript
Mar 08, 2023

€22.4 (+1.82%)

Earnings
Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Q3 2022 Mirum Pharmaceuticals Inc Earnings Call Transcript
Nov 09, 2022

€23.4

Earnings
Mirum Pharmaceuticals Inc To Discuss The Topline Data From the MARCH Study Call Transcript
Oct 24, 2022
Q2 2022 Mirum Pharmaceuticals Inc Earnings Call Transcript
Aug 04, 2022

€22.6 (+0.89%)

Earnings
Q1 2022 Mirum Pharmaceuticals Inc Earnings Call Transcript
May 05, 2022

€22 (-2.65%)

Earnings
Q4 2021 Mirum Pharmaceuticals Inc Earnings Call Transcript
Mar 09, 2022

€19.24 (-0.21%)

Earnings
Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Q3 2021 Mirum Pharmaceuticals Inc Earnings Call Transcript
Nov 15, 2021

€13.41 (-2.15%)

Earnings
Mirum Pharmaceuticals Inc To Discuss FDA Approves LIVMARLI Call Transcript
Sep 29, 2021
Q2 2021 Mirum Pharmaceuticals Inc Earnings Call Transcript
Aug 05, 2021

Earnings
Q1 2021 Mirum Pharmaceuticals Inc Earnings Call Transcript
May 06, 2021

Earnings
Mirum Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2021
Mirum Pharmaceuticals Inc Corporate Analyst Meeting Transcript
Dec 09, 2020

Q3 2023 Mirum Pharmaceuticals Inc Earnings Call Transcript

Nov 02, 2023 / 08:30PM GMT

Release Date Price: €26.6 (+3.91%)

Transcript 10-Q8-K

Operator

Good afternoon. I would like to welcome you all to the Mirum Pharmaceuticals Conference Call. My name is Brika and I'll be the event specialist running today's call with you.

(Operator Instructions) I would now like to pass the call over to your host, Andrew McKibben, Vice President of Investor Relations to begin. So Andrew, you may begin.

Andrew McKibben

Mirum Pharmaceuticals, Inc. - VP of IR and Finance

Thanks, Brika, and good afternoon, everyone. I'd like to welcome you to Mirum Pharmaceuticals' Third Quarter 2023 Conference Call. I'm joined today by our President and CEO, Chris Peetz; our Chief Operating Officer, Peter Radovich, our Head of Research and Development, Pam Vig and our newest team member Eric Bjerkholt, our Chief Financial Officer. Earlier today, Mirum issued a news release announcing the company's results for the third quarter of 2023. Copies of this news release and SEC filings can be found in the Investors section of our website. Full details and updates from the quarter can be found in our news release and 10-Q issued today.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.